These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 25925721)

  • 1. Epitope targeting of tertiary protein structure enables target-guided synthesis of a potent in-cell inhibitor of botulinum neurotoxin.
    Farrow B; Wong M; Malette J; Lai B; Deyle KM; Das S; Nag A; Agnew HD; Heath JR
    Angew Chem Int Ed Engl; 2015 Jun; 54(24):7114-9. PubMed ID: 25925721
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interactions of a potent cyclic peptide inhibitor with the light chain of botulinum neurotoxin A: Insights from X-ray crystallography.
    Kumaran D; Adler M; Levit M; Krebs M; Sweeney R; Swaminathan S
    Bioorg Med Chem; 2015 Nov; 23(22):7264-73. PubMed ID: 26522088
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metal Ions Effectively Ablate the Action of Botulinum Neurotoxin A.
    Bremer PT; Pellett S; Carolan JP; Tepp WH; Eubanks LM; Allen KN; Johnson EA; Janda KD
    J Am Chem Soc; 2017 May; 139(21):7264-7272. PubMed ID: 28475321
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mechanism of inhibition of botulinum neurotoxin type A light chain by two quinolinol compounds.
    Minnow YV; Goldberg R; Tummalapalli SR; Rotella DP; Goodey NM
    Arch Biochem Biophys; 2017 Mar; 618():15-22. PubMed ID: 28137423
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis of substrates and inhibitors of botulinum neurotoxin type A metalloprotease.
    Sukonpan C; Oost T; Goodnough M; Tepp W; Johnson EA; Rich DH
    J Pept Res; 2004 Feb; 63(2):181-93. PubMed ID: 15009541
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The C-terminal heavy-chain domain of botulinum neurotoxin a is not the only site that binds neurons, as the N-terminal heavy-chain domain also plays a very active role in toxin-cell binding and interactions.
    Ayyar BV; Aoki KR; Atassi MZ
    Infect Immun; 2015 Apr; 83(4):1465-76. PubMed ID: 25624352
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Regions on the Light Chain of Botulinum Neurotoxin Type A Recognized by T Cells from Toxin-Treated Cervical Dystonia Patients. The Complete Human T-Cell Recognition Map of the Toxin Molecule.
    Oshima M; Deitiker P; Jankovic J; Atassi MZ
    Immunol Invest; 2018 Jan; 47(1):18-39. PubMed ID: 28891721
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Iterative structure-based peptide-like inhibitor design against the botulinum neurotoxin serotype A.
    Zuniga JE; Hammill JT; Drory O; Nuss JE; Burnett JC; Gussio R; Wipf P; Bavari S; Brunger AT
    PLoS One; 2010 Jun; 5(6):e11378. PubMed ID: 20614028
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A high-affinity competitive inhibitor of type A botulinum neurotoxin protease activity.
    Schmidt JJ; Stafford RG
    FEBS Lett; 2002 Dec; 532(3):423-6. PubMed ID: 12482605
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Systematic discovery of molecular probes targeting multiple non-orthosteric and spatially distinct sites in the botulinum neurotoxin subtype A (BoNT/A).
    Dadgar S; Floriano WB
    Mol Cell Probes; 2015 Jun; 29(3):135-43. PubMed ID: 25745992
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Botulinum neurotoxin inhibitor binding dynamics and kinetics relevant for drug design.
    Patel KB; Kononova O; Cai S; Barsegov V; Parmar VS; Kumar R; Singh BR
    Biochim Biophys Acta Gen Subj; 2021 Sep; 1865(9):129933. PubMed ID: 34023445
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quinolinol and peptide inhibitors of zinc protease in botulinum neurotoxin A: effects of zinc ion and peptides on inhibition.
    Lai H; Feng M; Roxas-Duncan V; Dakshanamurthy S; Smith LA; Yang DC
    Arch Biochem Biophys; 2009 Nov; 491(1-2):75-84. PubMed ID: 19772855
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The C terminus of the catalytic domain of type A botulinum neurotoxin may facilitate product release from the active site.
    Mizanur RM; Frasca V; Swaminathan S; Bavari S; Webb R; Smith LA; Ahmed SA
    J Biol Chem; 2013 Aug; 288(33):24223-33. PubMed ID: 23779108
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fine and domain-level epitope mapping of botulinum neurotoxin type A neutralizing antibodies by yeast surface display.
    Levy R; Forsyth CM; LaPorte SL; Geren IN; Smith LA; Marks JD
    J Mol Biol; 2007 Jan; 365(1):196-210. PubMed ID: 17059824
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Benzoquinones as inhibitors of botulinum neurotoxin serotype A.
    Bremer PT; Hixon MS; Janda KD
    Bioorg Med Chem; 2014 Aug; 22(15):3971-81. PubMed ID: 24984937
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Peptide inhibitors targeting Clostridium difficile toxins A and B.
    Abdeen SJ; Swett RJ; Feig AL
    ACS Chem Biol; 2010 Dec; 5(12):1097-103. PubMed ID: 20863124
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Substrate-based inhibitors exhibiting excellent protective and therapeutic effects against Botulinum Neurotoxin A intoxication.
    Guo J; Wang J; Gao S; Ji B; Waichi Chan E; Chen S
    Sci Rep; 2015 Nov; 5():16981. PubMed ID: 26584873
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Strategies to Counteract Botulinum Neurotoxin A: Nature's Deadliest Biomolecule.
    Lin L; Olson ME; Eubanks LM; Janda KD
    Acc Chem Res; 2019 Aug; 52(8):2322-2331. PubMed ID: 31322847
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Uptake of botulinum neurotoxin into cultured neurons.
    Keller JE; Cai F; Neale EA
    Biochemistry; 2004 Jan; 43(2):526-32. PubMed ID: 14717608
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Screening of botulinum neurotoxin type A-binding peptides by phage display peptide library].
    Shi J; Wang H; Yin J; Hou XJ
    Wei Sheng Wu Xue Bao; 2006 Feb; 46(1):136-8. PubMed ID: 16579481
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.